New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - salbutamol 50 µg/ml - solution for injection - 50 mcg/ml - active: salbutamol 50 µg/ml

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - salbutamol 4 mg/ml equivalent to 200 µg/dose - aerosol inhaler, metered dose - 200 mcg/dose - active: salbutamol 4 mg/ml equivalent to 200 µg/dose excipient: dichlorodifluoromethane lecithin sorbitan trioleate trichlorofluoromethane

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - salbutamol sulfate 5 mg/ml - solution for inhalation - 5 mg/ml - active: salbutamol sulfate 5 mg/ml

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

bayer schering pharma - salbutamol - pressurised inhalation, solution - 100 µg

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - digoxin 0.05 mg/ml;   - elixir - 0.05 mg/ml - active: digoxin 0.05 mg/ml   excipient: citric acid monohydrate dibasic sodium phosphate ethanol lime flavour 70.80.0303 methyl hydroxybenzoate propylene glycol purified water quinoline yellow sucrose - lanoxin is indicated in the management of chronic cardiac failure where the dominant problem is systolic dysfunction. its therapeutic benefit is greatest in those patients with ventricular dilatation. lanoxin is specifically indicated where cardiac failure is accompanied by atrial fibrillation.